What are Average Wholesale Prices (AWP) and why are they significant?

Average Wholesale Prices (AWP) are benchmarks used in the pharmaceutical industry for drug reimbursement. Disputes and litigation surrounding these benchmarks can have significant financial implications for companies involved in drug distribution and pricing.

What is the potential impact of this settlement on McKesson Corporation?

This settlement is expected to resolve ongoing legal disputes, which should reduce financial uncertainty and potential liabilities for McKesson. The resolution of these claims generally provides a clearer path forward for the company's operations and financial planning.

Where can I find more details about this settlement?

More details about the settlement can be found in the press release issued by McKesson Corporation on November 21, 2008, which is attached as Exhibit 99.1 to this 8-K filing.

MCK 8-K SEC Disclosure — Nov 21, 2008

Q: What is the main purpose of this 8-K filing?

The main purpose of this 8-K filing is to announce that McKesson Corporation has reached an agreement to settle all private party claims related to First DataBank's published drug reimbursement benchmarks (Average Wholesale Prices or AWP).

Summary

McKesson Corporation (MCK) filed an 8-K on November 21, 2008, to announce a significant development regarding litigation. The company has reached an agreement to settle all private party claims related to First DataBank's published drug reimbursement benchmarks, commonly known as Average Wholesale Prices (AWP). This settlement is a crucial event for investors as it aims to resolve ongoing legal disputes that could have had a material impact on the company's financial performance and future operations. The resolution of these claims provides greater clarity and reduces uncertainty, which is generally viewed positively by the market.

Key Highlights

1McKesson Corporation announced an agreement to settle all private party claims related to First DataBank's Average Wholesale Prices (AWP).
2The settlement resolves ongoing litigation concerning drug reimbursement benchmarks.
3This filing is an 8-K report, indicating a material event.
4The press release detailing the settlement is attached as an exhibit.
5The event date reported is November 20, 2008, with the filing date of November 21, 2008.

MCKESSON CORP 8-K Report, Corporate Update (Nov 21, 2008)

Summary

Key Highlights

Frequently Asked Questions